Chronic lung infection in cystic fibrosis is characteristically associated with polyagglutinable, serumsensitive, mucoid strains of Pseudomonas aeruginosa. Enzyme-linked immunosorbent assay (ELISA) methods for standard-free quantitation of immunoglobulin G (IgG) and IgM antibodies to P. aeruginosa lipopolysaccharides (LPSs) have been developed. We now report the development of assays for quantitation of monomer and dimer total IgA and IgA anti-LPS antibodies. Use of these methods in diagnosis of early chronic P. aeruginosa lung infection was assessed. IgG and IgA anti-LPS levels increased significantly at the onset of chronic infection and continued to increase to very high levels in the later stages of infection. IgM anti-LPS levels also rose at the onset of chronic infection but did not increase further. The function of true-and false-positive rates was illustrated by using various concentrations of IgG, IgA, and IgM anti-LPS for discrimination of patients. Values that gave optimum separations were used for statistical evaluation of the diagnostic sensitivities and specificities of anti-LPS antibody concentrations. The results obtained in these assays were compared with a diagnosis, based on the number of precipitins in crossed immunoelectrophoresis, of serum samples from cystic fibrosis patients. In 64 paired serum samples taken before and immediately after the onset of chronic infection, as defined by crossed inimunoelectrophoresis precipitins, the predictive values of a positive ELISA were 86% for IgG and 89% for IgA. The predictive values for a negative ELISA were 98% for IgG and 97% for IgA. Results of the IgM anti-LPS ELISA had a lower predictive value. Immunoblotting and absorption studies showed that IgG anti-LPS antibodies were directed specifically against LPS of P. aeruginosa. ELISAs were developed to determine the specific IgG subclasses involved. The increase in IgG anti-LPS involved all four subclasses. Highest anti-LPS titers were seen with IgGl and IgG4, but the largest relative increases were seen with IgG2 and IgG3.
Chronic pulmonary infection with Pseudomonas aeruginosa is characteristic of cystic fibrosis (CF) patients and is the major factor determining the severity of illness and mortality (28) . After a period of relatively harmless colonization of the mucosal lining by P. aeruginosa, the clinical condition begins to deteriorate and symptoms of respiratory infection increase. Although long-term eradication of P. aeruginosa, once the infection has become established, is seldom achieved, exacerbations can be brought into remission by regular intensive antibiotic treatment. Early and active treatment regimens improve the lung function, wellbeing, and long-term survival of patients (20) . It is therefore important to identify the early stages of infection and the appropriate time to start intensive antimicrobial therapy.
The establishment of chronic invasive, tissue-destroying infection is associated with characteristic changes in the bacteria. Thus, P. aeruginosa isolated from sputum of CF patients with chronic pulmonary infection are often mucoid, serum sensitive, and polyagglutinable (14) . We have previously shown that the lipopolysaccharide (LPS) (O antigen; endotoxin) of polyagglutinating clinical isolates is deficient in the O-polysaccharide chain but conserved in the core oligosaccharide and lipid A part of the molecule (5) . The prevalence of 0-deficient strains in which common antigenic sites are accessible to antibodies makes the LPS of such strains potentially useful in diagnostic assays of chronic lung infection. Serological assays determining antibodies to P. aeruginosa (1, 2, 19, 23) and P. aeruginosa products (12, 16, 21) have previously been found to be of value in monitoring both the course of infection and treatment. However, none of the tests using single antigens has been able to detect the antibody response in all P. aeruginosa-infected CF patients. The number of different kinds of precipitating antibodies (precipitins) against P. aeruginosa whole-cell sonic extracts rises during the infection and is used in combination with bacteriological criteria to diagnose the onset of chronic P. aeruginosa lung infection in Danish CF patients (15) . However, more sensitive assays detecting antibodies of different classes and subclasses specific for defined antigens would be useful for characterization of early specific antibody responses in these patients. Information about specific antibody responses could be especially useful in the early diagnosis of cases in which there is a rapid development of the lung infection.
In a longitudinal study of concentrations in serum of antibodies to Pseudomonas LPSs during the course of chronic lung infection in CF patients, we found a good positive correlation between immunoglobulin (IgG) antibodies to LPS from a clinical isolate of P. aeruginosa 0:3/9 and the number of precipitins to Pseudomonas sonic extracts (8) . An increase in the number of precipitins, in turn, reflects the severity of the disease (8, 15 (28) . Noncolonized CF patients were defined as CF patients with no growth of P. aeruginosa in sputum at monthly examinations and with no or one precipitin in crossed immunoelectrophoresis (CIE) . The onset of chronic P. aeruginosa lung infection was defined as the point at which the bacteria had been found in every sputum sample for at least 6 months and serum contained two or more CIE precipitins to P. aeruginosa (15) . Serum samples obtained while the patients were noncolonized (CFO) were available from 64 patients. These were paired with the first serum samples taken after the onset of chronic P. aeruginosa lung infection (CF+) for enzyme-linked immunosorbent assay (ELISA) determination of IgM, IgG, and IgA anti-Pseudomonas LPS antibody concentrations. Serum samples from 10 CF patients with lung infection for 8 to 16 years who showed consistent growth of P. aeruginosa in sputum were examined for precipitins and anti-LPS antibodies and used as examples of samples from patients with late chronic infection (CF+ +).
LPS antigens. A polyagglutinating mucoid P. aeruginosa 170 0-group 3/9 bacteriophage type 21,48,68,109,352,1214, F3,M4,colll+ was isolated from sputum of a CF patient with chronic pulmonary infection. LPS was extracted by the phenol-chloroform-petroleum ether method (10) . The LPS was purified by successive ultracentrifugation steps, purged of associated inorganic cations and low-molecular-weight basic amines by electrodialysis (9) , and converted to its uniform triethylamine salt form. The detailed chemical composition and immunochemical characterization of this Opolysaccharide-deficient LPS are reported elsewhere (5) .
Pseudomonas standard antigens. Water-soluble antigens from P. aeruginosa strains representing the 17 serotypes of the International Antigen Typing Scheme were prepared as previously described (15) (17) .
ELISA for anti-P. aeruginosa LPS IgG subclasses. ELISAs were developed to investigate the distribution and development of specific anti-P. aeruginosa 0:3/9 LPS IgG subclasses. Serum samples from healthy donors were used to optimize the incubation conditions. Use of sera from healthy persons ensured the development of an assay sensitive enough to measure anti-LPS antibodies in healthy controls and in noncolonized CF patients. The optimal concentrations for the conjugates were determined as previously described (3) . For assay of anti-LPS IgG subclasses, peroxidase-conjugated mouse monoclonal antibodies specific for human IgGl (1:5,000), IgG2 (1:1,000), IgG3 (1:500), or IgG4 (1:1,000) in PBS-Tween 20 (Janssen Biochemica, Beerse, Belgium) were used. Coating of microtest plates, incubation times, and experimental conditions were as described above. Anti-LPS IgGl to -4 titers were expressed as the reciprocal dilutions of samples corresponding to an A492 of 0.500.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting. LPS preparations from P. aeruginosa F-D1 (0:6) and clinical isolates 1118 (0:3), 174 (0:9), 170 (0:3/9), 15704/83 (0:3/6/9/10), and 14580/83 (0:3/6/9/10) (5) and from Shigella sonnei, Klebsiella pneumoniae, Salmonella minnesota R60 (Ra), Escherichia sulfate-10% sucrose-0.01% bromphenol blue and separated on a sodium dodecyl sulfate-polyacrylamide gel containing 5 and 14% acrylamide in the stacking and separating gels, respectively. Gels were silver stained (26) or the samples were transferred to nitrocellulose paper as previously described (8) . After blocking in 1% gelatin-Tris-buffered saline (TSG), the nitrocellulose paper was incubated for 2 h with CF serum diluted 1:500 in TSG. The nitrocellulose paper was then washed three times in Tris-buffered saline and incubated for 1 h with peroxidase-conjugated rabbit antibodies to human IgG, IgM, or IgA (Dakopatts) diluted 1:200 in TSG. Color was developed in 0.003% (wt/vol) 4-chloro-1-naphthol-0.05% (vol/vol) H202.
Precipitating antibodies against P. aeruginosa. P. aeruginosa precipitins were determined by CIE as described earlier (15) . Briefly, 2 ,ud of the standard antigen preparation (22 ,ug/ml of protein) was applied to a well and separated in the first dimension (10 V/cm, 1 h) in 1% agarose gels. Second-dimension separation was performed for 18 h at 1 to 2 V/cm into 1% agarose containing 15 Fig. 2 . Identical maximal bound enzyme activity as well as parallel dilution curves of serum and colostrum IgA indicate that the a-chain was detected with equal efficiency regardless of molecular configuration.
The dose-response curve of IgA anti-P. aeruginosa LPS in the standard CF serum pool was assayed simultaneously to confirm parallelism with the IgA standard curve (Fig. 2) . The detection limit of IgA bound by anti-IgA or LPS, defined as the lowest concentration of IgA significantly different from 0 at the 95% confidence limit, was below 8.4 ,ug/liter (in 15 assays). The relative standard intra-and interassay deviation and the plate-to-plate variation on different days for assay of IgA anti-P. aeruginosa LPS (range, 0.5 to 100 ,ug/ml) in 15 serum samples of low (5 samples), medium (5 samples), and high (5 samples) antibody concentrations were 4, 8, and 10%, respectively.
Anti-Pseudomonas LPS antibody concentrations. shows the number of precipitins in CIE and the concentrations of anti-LPS antibodies in healthy subjects and CF patients. The number of precipitins in normal subjects was zero to one. In contrast, the IgM, IgG, and IgA anti-P. aeruginosa LPS antibody concentrations in normal subjects were age related. The IgG and IgA anti-LPS antibody concentrations reached the highest levels in adults, whereas IgM anti-P. aeruginosa LPS concentrations reached the highest levels in children. The median IgA anti-P. aeruginosa LPS concentrations were the same for healthy subjects and CF patients before the onset of chronic lung infection (CFO) but increased significantly (P < 0.001, paired t test) in CF patients at the onset of chronic infection (CF+). IgG and IgA anti-LPS concentrations and the number of precipitins continued to rise to very high levels in later stages of the infection (Table 1 ). In contrast, the median concentrations of IgM anti-P. aeruginosa LPS antibodies increased from normals, via CFO to CF+ patients, after which no further increase was found. In fact, there was a small decrease in median IgM anti-P. aeruginosa LPS in early (CF+) and late (CF+ +) chronically infected patients (Table 1 ). Figure 3 shows the distribution of IgG, IgA, and IgM anti-P. aeruginosa LPS antibodies among healthy subjects and 64 CF patients before and immediately after diagnosis of chronic P. aeruginosa lung infection. Significant differences were observed in the distribution of IgG, IgA, and IgM anti-LPS antibodies among the three groups (normal subjects, CFO patients, and CF+ patients; P < 0.001 in all three cases, chi-square test). There was, however, some overlap in IgG and IgA anti-LPS concentrations between CFO and CF+ patients (Fig. 3) .
The nosographic sensitivities and specificities of the anti-P. aeruginosa LPS ELISAs were evaluated in CF+ and CFO samples defined as infected and noninfected, respectively, by the CIE test ( Table 2 ). The predictive value of a positive anti-LPS ELISA (PVPS), used to detect early P. aeruginosa infection, was the diagnostic specificity, and the predictive Table 2) .
The values of the IgG and IgA anti-LPS concentrations used to distinguish chronically infected CF patients from uninfected subjects may, however, be chosen differently and are a balance of false-positive and false-negative results. The successive overlap between CF+ and healthy subjects as well as between CF+ and CFO patients can be illustrated for the IgG, IgA, and IgM anti-LPS ELISAs by means of receiver-operating characteristic curves (27) , i.e., the relationship between the true-positive rate (rate of positives among patients with infection) and the false-positive rate (rate of positives among patients without infection), when the criterion of positive varies over the range of anti-LPS concentrations (Fig. 4) . By using this method, the concentrations of anti-LPS antibodies resulting in the minimal overlap of CF+ and CFO patients, as defined by CIE precipitins, was found and used to evaluate the diagnostic values presented above. Figure 4 shows equally good separation of CF+ and CFO patients by the IgG and the IgA anti-P. aeruginosa LPS ELISAs. The IgM anti-LPS curve was always lower than the IgG and IgA anti-LPS curves, demonstrating less separation of patients by IgM anti-LPS regardless of the concentrations chosen. Figure 4 also Specificity of anti-LPS antibodies. The specificities of the anti-P. aeruginosa LPS antibodies in sera with elevated anti-LPS concentrations were investigated further. The anti-P. aeruginosa LPS antibodies could in each case be absorbed by P. aeruginosa 0:3/9 LPS coated onto sheep erythrocytes (11) . None of the 10 CFO serum samples with elevated IgG anti-P. aeruginosa LPS antibody concentrations had elevated (>40 ptg/ml) concentrations of antibodies to other LPSs (including strains of E. coli and of Salmonella and Serratia species) as measured by ELISA (6) . In immunoblotting, IgG anti-LPS antibodies in the 10 CFO serum samples with elevated IgG anti-P. aeruginosa LPS concentrations reacted to P. aeruginosa 0:3/9 LPS and also to LPSs from other clinical isolates of P. aeruginosa but only very weakly to LPSs of other gram-negative bacteria (Fig.   5 ).
Anti-P. aeruginosa IgG subclasses. Figure 6 shows the distribution of the IgG subclass specificity of the anti-LPS antibodies of normal subjects and CFO and CF+ patients. 
DISCUSSION
A sandwich ELISA for quantitation of total IgA was developed by using microtest plates and commercially available reagents. The quantitative results of IgA levels in sera obtained with this ELISA correlated well (r, 0.96) with those obtained by traditional rocket immunoelectrophoresis (Fig.  1) . The high sensitivity and demonstrated detection of achains in both monomer and secretory dimer forms makes this ELISA convenient for measuring total IgA in sera and secretions. In comparison with rocket immunoelectrophoresis, the ELISA for total IgA has a higher capacity, is more sensitive, and is simpler, faster, and less expensive.
In this study, ELISA for total IgA was used together with an indirect ELISA for IgA anti-LPS antibodies to quantitate specific IgA anti-P. aeruginosa LPS antibodies in a combined design (Fig. 2) . By reading the anti-LPS concentration on the simultaneously performed standard curve for total IgA, the amounts of specific anti-LPS antibodies could be conveniently estimated in the CF serum pool as described earlier (6) . The same principle was used for quantitation of the IgG and IgM anti-P. aeruginosa antibodies in normal subjects and CF patients.
The results showed that there was no significant difference in the number of precipitins and the median IgA anti-P. aeruginosa LPS antibody concentrations between healthy subjects and CF0 patients. In contrast, the median concentration of IgM anti-P. aeruginosa LPS antibodies and, to a lesser extent, IgG anti-LPS, increased from levels in agematched normals, via CFO to CF+ patients. No further increase in IgM anti-LPS was then found. In fact, there was a small decrease in median IgM anti-P. aeruginosa LPS from early (CF+) and late (CF+ +) chronically infected patients (Table 2 ). These findings are in agreement with earlier results and are consistent with IgM being an early and IgG a later immune response to bacterial infections (4, 8) . The less pronounced and persistent IgM anti-LPS response is also consistent with LPS being a T-cell-independent antigen (4).
Establishment of a diagnostic test defining the onset of chronic lung infection is complicated because the increase in concentrations of anti-P. aeruginosa LPS antibodies other than IgM is a continuum toward extremely high values in the later stages of infection (Table 1; 8) . A useful definition of the onset of chronic P. aeruginosa lung infection is the demonstration of two or more precipitins against P. aeruginosa whole-cell sonic extracts in CIE (15) . A comparison was therefore made of the diagnostic values of the anti-LPS ELISAs and CIE. By these criteria, the IgM anti-P. aeruginosa LPS concentration in serum was of less diagnostic significance than the concentrations of anti-LPS IgG and IgA (Fig. 3) . The nosographic specificities and sensitivities of the IgG and IgA anti-P. aeruginosa LPS ELISAs were higher and showed both high PVPOS (86 and 89%) and high PVneg (98 and 97%) ( Table 2 ). The concentrations of IgG and IgA anti-P. aeruginosa LPS antibodies chosen for evaluation of the anti-LPS ELISA as a diagnostic test are the points of minimal overlap between the groups tested (CF+ versus CFO) (Fig. 4) 
